China
Africa
Explore chapters and articles related to this topic
Transfusion service management
Published in Jennifer Duguid, Lawrence Tim Goodnough, Michael J. Desmond, Transfusion Medicine in Practice, 2020
James P AuBuchon, Dafydd W Thomas
Other laboratory services that relate frequently to transfusion medicine include hematology and coagulation. A process as simple as notification from the hematology laboratory to the transfusion service that a new diagnosis of acute leukemia has been made may allow the transfusion service to place appropriate component restrictions within their records. Coagulation testing may identify patients with certain diseases or with particular coagulopathic states that may require the assistance of the transfusion service (or its consulting physician). These intralaboratory connections may appear obvious, but their codification may transfer information that will improve patient care and take stress out of the provision of blood components.
Laboratory Instrumentation, Reagents, Methods, and Patient Sample as Variables in Coagulation
Published in Harold R. Schumacher, William A. Rock, Sanford A. Stass, Handbook of Hematologic Pathology, 2019
James W. Cook, William A. Rock
With electronics and automation, an unreasonable reliance on the implied accuracy of instrumentation emerged which made the result the “truth” without an understanding as to how that value was achieved. In this chapter we discuss the variability of coagulation testing with a majority of the current instrumentation. This approach will help the reader analyze an electronic and automated system with an eye for what can go wrong. We anticipate that the reader will then be able to ask the right questions when reviewing the results, to assure the best interpretation.
Emerging Potential of In Vitro Diagnostic Devices: Applications and Current Status
Published in Debarshi Kar Mahapatra, Sanjay Kumar Bharti, Medicinal Chemistry with Pharmaceutical Product Development, 2019
Swarnali Das Paul, Gunjan Jeswani
There are many more other applications of IVD. They are including tests for genetic disorder, enzyme screening tests, tests for hematology, tests for metabolism, etc. Tests intended for an inherited or acquired genetic marker, including: detecting the Philadelphia chromosome, prenatal genetic screening tests for Huntington’s disease, cystic fibrosis and many more. IVDs are also helpful in monitoring biological components, including acute cardiac markers such as, Troponin T, Troponin I, and CKMB. Even congenital disorders can be detected by in vitro testing devices. Alpha fetoprotein (AFP) marker for fetal open neural tube defects is detected by IVD. Much software is embedded as a part of IVD. One such example is software for the analysis of results acquired in the first trimester to detecting fetal risk of trisomy. IVDs are also employed for performing coagulation testing, including factor assays, activated partial thromboplastin time (APTT) and prothrombin time testing. IVDs are also intended for therapeutic checking of the impact of incorrect use of immunosuppressive drugs such as, tacrolimus and cyclosporin, and for detecting their adverse transplantation consequence.
Predictive value of thromboelastography for postoperative lower extremity deep venous thrombosis in gastric cancer complicated with portal hypertension patients
Published in Clinical and Experimental Hypertension, 2021
Chunhong Gong, Kaihu Yu, Nianrong Zhang, Juan Huang
Clinical studies have also shown that tumor itself is an independent risk factor for LDVT, and the risk of venous thrombosis in tumor patients is 6 times that of non-tumor patients (5,6). The latest clinical data point out that if patients with gastrointestinal tumors do not undergo preventive anticoagulation treatment after surgery, the risk of LDVT can increase by 46% (7). Gastric cancer is one of the most common malignant tumors of the digestive system. Among them, the morbidity rate ranks first among all types of tumors, and the morbidity and mortality rates are increasing year by year. The risk of venous thrombosis in gastric cancer is 15.8 times that of healthy people, so it is particularly important to detect the coagulation status of gastric cancer patients after surgery (8,9). It is worth noting that portal hypertension is also an independent risk factor for thrombosis. However, the current routine clinical coagulation testing items cannot continuously and completely monitor the dynamic status of coagulation in patients.
Hemostatic defects in massive transfusion: an update and treatment recommendations
Published in Expert Review of Hematology, 2021
A more recent study of 278 patients with TIC (median ISS 17, mortality 26%) confirmed that 31% of these patients had both abnormal conventional and viscoelastic assays. Interestingly, patients with abnormal conventional coagulation assays were more severely injured, and had significantly higher mortality. Mortality was significantly higher in patients with coagulation abnormalities in conventional (40%) and both conventional/viscoelastic (49%) coagulation testing than in those with coagulation abnormalities only in viscoelastic testing (6%, p < 0.017). The study authors concluded that patients with discordant coagulopathies reflect different clinical phenotypes in TIC, and that abnormal conventional assays were associated with significant coagulation factors deficiencies. They also concluded that although TEG-guided resuscitation improves survival after injury, INR and PTT identify coagulopathic patients with highest mortality regardless of TEG and likely represent distinct mechanisms independent of biochemical clot strength. [47]
Does plateletpheresis induce a hypercoagulable state? A global assessment of donor’s hemostatic system by ROTEM
Published in Platelets, 2019
O. Meltem Akay, Fatih Taştekin, Ertuğrul Çolak
In the last decade, thromboelastometry has became a valuable tool of coagulation testing for the diagnosis and management of hemostatic disorders. Thromboelastometry is a technique that provides data about the entire coagulation system, from the beginning of clot formation to fibrinolysis, involving both cellular and plasma components of hemostasis. Rotational thromboelastometry (ROTEM) which evolved from thromboelastometry technology avoids several limitations of classical method while maintaining a good correlation with conventional thromboelastometry determination. The most important benefits of ROTEM technology include the rapid availability of test results, less susceptibility to mechanical stress, movement and vibration; as well as providing enhanced reproducibility [11]. The data is also continuous, digital, and retrievable for further calculations [12].